YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose's common stock will trade on the Nasdaq Global Select Market ("Nasdaq") on a split-adjusted basis under a new CUSIP number 68404V209 ...

YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 1:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will b ...

OptiNose, Inc. (NASDAQ:OPTN) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jonathan Neely - Vice President of Investor Relations and Business Development Ramy Mahmoud - Chief Executive Officer Terry Kohler - Chief Financial Officer Paul Spence - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets David Amsellem - Piper Sandler Glen Santangelo - Jefferies Matthew Caufield - H.C. Wainwright Operator Good day, and welcome to the ...

optinose® | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Building a Leading ENT / Allergy | | | | | | | | | | | | Specialty Company | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | November 12, 2024 | | | | | | | | | | | | | | | | | | | | | | | | | | 2 Forward-Looking Statements This presentation and our accompanying remarks contain "forward-looking statements" with ...

OptiNose (OPTN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.08 per share when it actually produced a loss of $0.07, delivering a surprise of 12.50%.Over the last four quarters, the compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (S ...

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating e ...

Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating expenses guidance to be between $90.0 to $93.0 million Conference call and webcast to b ...

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and developmen ...

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, "EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials"1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society. As discussed in the p ...